Breakpoints for posaconazole susceptibility testing: Background and discussion about the need of establishing values

Mycoses

Volumn 51, Issue SUPPL. 2, 2008, Pages 1-4

  Fleck, R ^a   Hof, H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aspergillus; Breakpoints; Candida; Posaconazole; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; PRIORITY JOURNAL; QUALITY CONTROL;

ANTIBIOTICS, ANTIFUNGAL; DRUG RESISTANCE, FUNGAL; ENDPOINT DETERMINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; TRIAZOLES;

ASPERGILLUS; ASPERGILLUS TERREUS; CANDIDA; FUNGI; ZYGOMYCETES;

EID: 47949085607     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01568.x     Document Type: Article

References (28)

1. Lortholary O, Dannaoui E, Raoux D et al. In vitro susceptibility to posaconazole of 1903 yeast isolates recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2007 51 : 3378 80.
2. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002 46 : 1032 7.
3. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006 50 : 2009 15.
4. Hof H. A new, broad-spectrum azole antifungal: posaconazole-mechanisms of action and resistance, spectrum of activity. Mycoses 2006 49 (Suppl. 1 2 6.
5. Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int. J. Antimicrob. Agents 2001 18 : 167 72.
6. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006 42 : e61 5.
7. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 59.
8. Pfaller MA, Diekema DJ, Rex JH et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006 44 : 819 26.
9. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Second Edition M27-A2. Wayne, PA : Clinical and Laboratory Standards Institute (CLSI), 2002.
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard M38-A. Wayne, PA : Clinical and Laboratory Standards Institute (CLSI), 2002.
11. European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2002 Apr 14 (4 398 405.
12. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 2007 59 : 767 71.
13. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001 45 : 2862 4.
14. Franz R, Ruhnke M, Morschhauser J. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 1999 42 : 453 8.
15. Morace G, Amato G, Bistoni F et al. Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol 2002 40 : 2953 8.
16. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline M44-A. Wayne, PA : Clinical and Laboratory Standards Institute (CLSI), 2004.
17. Pfaller MA, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol 2005 43 : 5208 13.
18. Sims CR, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol 2006 44 : 2105 8.
19. Maxwell MJ, Messer SA, Hollis RJ et al. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol 2003 41 : 1087 90.
20. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005 43 : 3884 9.
21. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002 35 : 982 9.
22. Messer SA, Diekema DJ, Hollis RJ et al. Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J Clin Microbiol 2007 45 : 1322 4.
23. Diekema DJ, Messer SA, Hollis RJ et al. Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole. J Clin Microbiol 2007 45 : 1974 7.
24. Park BJ, Arthington-Skaggs BA, Hajjeh RA et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006 50 : 1287 92.
25. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997 40 : 401 14.
26. Denning DW, Venkateswarlu K, Oakley KL et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997 41 : 1364 8.
27. Lass-Florl C, Kofler G, Kropshofer G et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998 42 : 497 502.
28. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007 8 : 1167 78.